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1. Introduction  
The term meningitis implies inflammation of the leptomeninges and cerebrospinal fluid 
(CSF) in the subarachnoid space. Typically manifests as headache, neck stiffness, light 
sensitivity, and varying degrees of neurological symptoms and signs.  
The most common and often most severe forms of meningitis are due to infections, 
including bacteria, viruses, fungi, and parasites. Noninfectious causes of meningitis 
include primary inflammatory syndromes such as vasculitis and connective tissue 
disease, neoplasms of solid tumor and hematologic forms, and chemical irritants 
including certain medications, subarachnoid blood, and biologic matter spilling into CSF 
from tumors.  
Although a patient may present with symptoms of meningitis within days of onset, 
distinguishing acute from subacute or chronic meningitis may not always be possible early 
in the course. Nevertheless, the distinction is important because of the varying urgency, 
causes, and treatment strategy involved in each syndrome.  
In this review we summarize the current concepts of the approach to the treatment of adult 
meningitis and management of neurologic complications.  
2. Bacterial meningitis  
Bacterial meningitis is a medical, neurologic and sometimes neurosurgical emergency that 
requires a multidisciplinary approach. Bacterial meningitis has an annual incidence of 4 to 6 
cases per 100,000 adults, and Streptococcus pneumoniae and Neisseria meningitidis are 
responsible for 80 percent of all cases. Recommendations for antimicrobial therapy are 
changing as a result of the emergence of antimicrobial resistance. (Van de Beek et al., 2004; 
Schuchat et al., 2005; Van de Beek et al., 2006) 
In adults presenting with community-acquired acute bacterial meningitis, the sensitivity of 
the classic triad of fever, neck stiffness, and altered mental status is low (44%), but almost all 
such patients present with at least two of four symptoms — headache, fever, neck stiffness, 
and altered mental status (as defined by a score below 14 on the Glasgow Coma Scale). 
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2.1 Antimicrobial treatment 
The choice of antibiotic for empirical therapy is based on the possibility that a penicillin- and 
cephalosporin-resistant strain of S. pneumonia is the causative organism, and on the patient’s 
age and any associated conditions that may have predisposed to meningitis (table 1). 
 
Predisposing factor Common bacterial 
pathogens 
Initial intravenous antibiotic 
therapy 
Age: 2-50 years N meningitidis 
S pneumoniae 
Vancomycin plus 
ceftriaxone or cefotaxime* 
Age: >50 years N meningitidis 
S pneumoniae 
L monocytogenes, aerobic 
gram-negative bacilli 
**Vancomycin plus 
ceftriaxone or cefotaxime 
plus ampicillin 
With risk factor present 
(alcoholism or altered immune 
status) 
S pneumoniae 
L monocytogenes 
H influenzae 
**Vancomycin plus 
ceftriaxone or cefotaxime 
plus ampicillin 
*In areas with very low penicillin-resistance rates monotherapy penicillin may be 
considered 
**In areas with very low penicillin-resistance and cephalosporin-resistance rates 
combination therapy of amoxiciclin and a third-generation cephalosporin may be 
considered  
Table 1. Recommendations for empirical antimicrobial therapy in suspected community-
acquired bacterial meningitis (adapted from Van de Beek et al., 2006) 
For adults up to 50 years old from countries with high rates of pneumococcal penicillin- or 
cephalosporin-resistance, this should be a combination of either a third- or fourth-
generation cephalosporin plus vancomycin. In countries with very low rates of 
pneumococcal penicillin-resistance (such as The Netherlands) (Van de Beek et al., 2002), 
penicillin can still be used safely as a first-line agent. In the UK, the addition of vancomycin 
is also not considered necessary and is not recommended unless the patient presents from 
one of the geographic regions associated with high-level ceftriaxone resistance, such as 
Spain, Southern Africa, and certain parts of the USA. In adults older than 50 years, and in 
the immunocompromised patient, ampicillin should be added to this combination because 
of possible Listeria meningitis. (Nudelman & Tunkel, 2009; Schut et al., 2008; Van de Beek et 
al., 2006; Williams & Nadel, 2001) 
Once the bacterial pathogen is isolated and the sensitivity of the organism to the antibiotic is 
confirmed by in vitro testing, antimicrobial therapy should be modified accordingly. 
Recommendations for antibiotic therapy in bacterial meningitis are summarized in table 2-4 
and some important tips are: 
a. Bacterial meningitis due to S. pneumoniae, H. influenzae and group B streptococci is 
usually treated with intravenous antibiotics for 10–14 days. 
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b. Meningitis due to N. meningitidis is treated for 5–7 days. 
c. Patients with clinically suspected meningococcal meningitis who are treated with 
penicillin must be isolated for the first 24 h after initiation of antibiotic therapy and also 
treated with Rifampin 600 mg orally every 12 h for 2 days to eradicate nasopharyngeal 
colonization (penicillin does not eradicate the organisms in the nasopharynx). 
d. Meningitis due to L. monocytogenes and Enterobacteriaceae is treated for 3–4 weeks. 
e. Gentamicin is added to ampicillin in critically ill patients with L. monocytogenes 
meningitis. 
 
Pathogen Recommended 
therapy 
Adult dosage 
(intravenous) 
Days of therapy Alternative therapy 
Streptococcus 
pneumoniae 
  10 to 14 Meropenem, 
moxifloxacib or 
cloranfenicol 
Penicillin 
MIC: < 0,1 
mcg per mL 
Penicillin 4 million units 
every four hours 
  
Penicillin 
MIC: 0,1 to 1 
mcg per mL 
Ceftriaxone 2g every 12 hours   
Penicillin 
MIC:  1 mcg 
per mL 
Vancomycin 
plus 
Ceftriaxone 
15 to 22,5 mg per 
kg every 12 hours
2 g every 12 hours
  
Neisseria 
meningitidis 
Ceftriaxone 2 g every 12 hours 5 to 7 Chloranfenicol, 
meropenem or 
moxifloxacin 
Haemophilus 
influenza  
Ceftriaxone 2 g every 12 hours 7 to 10 Chloranfenicol or 
moxifloxacin 
Streptococcus 
agalactiae (group 
B streptococcus) 
Ampicillin 
plus 
Gentamicin 
Usually in 
children 
14 to 21 Vancomycin or 
cefotaxime 
Listeria 
monocitogenes 
Ampicillin 
with or without 
Gentamicin 
2 g every four 
hours 
1 to 2 mg per Kg 
every eight hours
21 
 
First 7 to 10 days
Trimethroprim/sulfam
ethoxazole 
Enterobacteriaceae Ceftriaxone, 
ceftazidime or 
cefepime 
varies 21 to 28 Ciprofloxacin, 
meropenem or 
Trimethroprim/sulfam
ethoxazole 
Staphylococci   7 to 10 days after 
shunt removal or 
cerebrospinal 
fluid sterilization
Daptomycin or 
lnezolid. Consider 
adding rifampicin 
Methicillin 
susceptible 
Nafcillin 2 g every four 
hours 
  
Methicillin 
resistant 
Vancomycin 15 to 22,5 mg per 
Kg every 12 hours
  
Table 2. Pathogen-specific therapy for common causes of bacterial meningitis 
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Treatment Dose 
Penicilin 2 million units every 4 h 
Amoxiclin or ampicillin 2 g every 4h 
Vancomycin 15 mg/Kg every 8h 
Third generation cephalosporins  
Ceftriaxone 2 g every 12h 
Cefotaxime 2 g every 4-6h  
Cefepime 2 g every 8h 
Ceftazidime 2 g every 8h 
Meropenem 2 g every 8h 
Chloramphenicol 1-1, 5g every 6h 
Fluroquinolones  
Gatifloxacin 400 mg every 24h 
Moxifloxacin 400 mg every 24h 
Trimethoprim-sulfamethoxazole 5 mg/kg every 6-12h 
Aztreonam 2 g every 6-8 h 
Ciprofloxacin 400 mg every 8-12h 
Rifampicin 600 mg every 12-24h 
Aminoglycoside (gentamicine) 1,7 mg/Kg every 8h 
Table 3. General recommendations for intravenous empirical antibiotic treatment 
Treatment Dose 
Rifampicin 600 mg twice daily for two days 
Ceftriaxone One dose 250 mg intramuscularly 
Ciprofloxacine One dose, 500 mg orally 
Azithromycin One dose, 500 mg orally 
Table 4. General recommendations for chemoprophylaxis 
2.2 Adjunctive dexamethasone 
A large randomized trial showed that dexamethasone (10 mg IV 15–20 min before or with 
the first dose of antibiotic and given every 6 h for 4 days) is beneficial in adults with acute 
bacterial meningitis. It reduced unfavorable outcome from 25% to 15% and mortality from 
15% to 7%. The benefits were most striking in patients with pneumococcal meningitis. 
Furthermore, patients on dexamethasone were less likely to have impaired consciousness, 
seizures and cardiorespiratory failure. Starting corticosteroids before or with the first dose 
of parenteral antimicrobial therapy appears to be more effective than starting corticosteroids 
after the first dose of antimicrobial therapy. For some adults with suspected meningitis, the 
beneficial effect of adjunctive dexamethasone is less certain, or may even be harmful. 
Therefore these patients should be carefully monitored throughout treatment. Steroids are 
not recommended in patients with postneurosurgical meningitis, those with a severe 
immunocompromised state, or in those who are hypersensitive to steroids. Patients with 
septic shock and adrenal insufficiency benefit from steroid therapy in physiological doses 
and longer duration. (Van de Beek et al., 2004; Van de Beek & de Gans, 2006; Fitch & Van de 
Beek, 2007; Nudelman & Tunkel, 2009; Schut et al., 2008; Van de Beek et al., 2006; Williams 
& Nadel, 2001; Weisfelt et al., 2006) 
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2.3 Monitoring of the patient and systemic complications 
Patients who are diagnosed with acute bacterial meningitis are at risk of various 
neurological and systemic complications and to detect them, patients should be admitted 
to intensive care unit where the following should be monitored: vital signs (blood 
pressure, heart rate, respiratory rate, temperature), oxygen saturation, level of 
consciousness, presence or absence of focal neurological signs or symptoms, papillary 
diameter and certain laboratory parameters, like CRP, leukocyte count, electrolytes, urea 
and creatinine. Analysis of arterial blood gases and measurement of serum lactate are 
important in patients in whom septic shock is suspected and the platelet count and 
coagulation tests are important in those in whom disseminated intravascular coagulation 
is suspected. (Van de Beek et al., 2006) 
Table 5 resumes the management of bacterial meningitis in Adults in the Intensive Care 
Unit.  
Bacterial meningitis is often associated with septic shock, which is an important predictor of 
outcome. It may manifest in several ways: hypotension (systolic pressure < 90 mm Hg or a 
reduction of >40 mm Hg from baseline) despite adequate fluid resuscitation, tachycardia 
(>100/min), tachypnea (>20/min), core body temperature >38°C or <36°C, drowsiness and 
oliguria (Pfister et al., 1993). 
Adrenocorticoid insufficiency in patients with septic shock must be treated with low doses 
of corticosteroids. Care should be taken to estimate and replace imperceptible fluid loss 
through the skin and lungs in patients who are febrile. 
Dyspnea, labored breathing, agitation, followed by progressive drowsiness, tachycardia, 
scattered crackles on pulmonary auscultation and hypoxemia point to the diagnosis of adult 
respiratory distress syndrome (ARDS). The chest x ray usually reveals characteristic diffuse 
alveolar interstitial infiltrates in all lung fields.  
Patients with bacterial meningitis are at risk of acute hyponatremia, although most cases are 
mild. Hyponatremia (serum sodium <135 mmol/l) on admission to hospital is found in 30% 
of patients (Brouwer et al,. 2007). Most episodes resolve within a few days without specific 
treatment and does not influence outcome. Severe hyponatremia (<130 mmol/l) is present 
in 6% of patients. 
An exceptionally high frequency of hyponatremia is seen in meningitis due to L. 
monocytogenes (73%) and S. pyogenes (58%). This complication may be a result of cerebral salt 
wasting, the syndrome of inappropriate antidiuretic hormone secretion or exacerbation by 
aggressive fluid resuscitation. This lack of clarity about the mechanism has resulted in the 
clinical dilemma about the management of intravenous fluids in bacterial meningitis 
(restricted or not). The goal should be to maintain a normovolemic state, and in patients 
with severe hyponatremia to use fluid maintenance therapy then fluid restriction, although 
there is no clear evidence supporting this approach. 
Hypernatremia (serum sodium >143 mmol/l) is less frequent and found on admission in 
only 7% of patients with culture-proven bacterial meningitis (Van de Beek et al., 2007). 
Patients with sodium levels >146 mmol/l (2% of patients) are more likely to have seizures 
before admission compared to those with lower levels. Sodium levels of >143 mmol/l are  
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Neurocritical care 
 
In patients with a high risk of brain herniation, consider monitoring intracranial pressure 
and intermittent administration of osmotic diuretics (mannitol [25%] or hypertonic [3%] 
saline) to maintain an intracranial pressure of <15 mm Hg and a cerebral perfusion 
pressure of ≥60 mm Hg 
Initiate repeated lumbar puncture, lumbar drain, or ventriculostomy in patients with acute 
hydrocephalus 
Electroencephalographic monitoring in patients with a history of seizures and fluctuating 
scores on the Glasgow Coma Scale 
Airway and respiratory care 
 
Intubate or provide noninvasive ventilation in patients with worsening consciousness 
(clinical and laboratory indicators for intubation include poor cough and pooling 
secretions, a respiratory rate of >35 per minute, arterial oxygen saturation of <90% or 
arterial partial pressure of oxygen of <60 mm Hg, and arterial partial pressure of carbon 
dioxide of >60 mm Hg) 
Maintain ventilatory support with intermittent mandatory ventilation, pressure-support 
ventilation, or continuous positive airway pressure 
Circulatory care 
 
In patients with septic shock, administer low doses of corticosteroids (if there is a poor 
response on corticotropin testing, indicating adrenocorticoid insufficiency, corticosteroids 
should be continued) 
Initiate inotropic agents (dopamine or milrinone) to maintain blood pressure (mean 
arterial pressure, 70–100 mm Hg) 
Initiate crystalloids or albumin (5%) to maintain adequate fluid balance 
Consider the use of a Swan–Ganz catheter to monitor hemodynamic measurements 
Gastrointestinal care 
 
Initiate nasogastric tube feeding of a standard nutrition formula 
Initiate prophylaxis with proton-pump inhibitors 
Other supportive care 
 
Administer subcutaneous heparin as prophylaxis against deep venous thrombosis 
Maintain normoglycemic state (serum glucose level, <150 mg per deciliter), with the use of 
sliding-scale regimens of insulin or continuous intravenous administration of insulin 
In patients with a body temperature of >40°C, use cooling by conduction or antipyretic 
agents 
Table 5. Management of Bacterial Meningitis in Adults in the Intensive Care Unit. 
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associated with a higher heart rate, lower CSF protein and lower CSF glucose levels. 
Hypernatremia is independently predictive of unfavorable outcome and mortality, however 
it is unclear if it reflects severe disease or directly contributes to the poor outcome. 
Physicians should be aware of the potential importance of hypernatraemia in patients 
presenting with bacterial meningitis and care should be taken in the fluid management.  
The coexistence of bacterial meningitis and arthritis has been described in several studies. It 
occurs in 7% of patients overall, more in meningococcal meningitis (12%) (Likitnukul et al., 
1986; Weisfeit et al., 2006). It is caused either by haematogenous bacterial seeding of joints 
(septic arthritis) or by immune-complex deposition in joints (immunomediated arthritis). A 
patient with immunomediated arthritis during meningococcal infection typically develops 
symptoms from day 5 of the illness or during recovery from the infection, generally 
involving the large joints. A definitive diagnosis of septic arthritis requires identification of 
bacteria in the synovial fluid by Gram stain or culture. The treatment of acute bacterial 
arthritis requires antibiotics and joint drainage. Although with some limitation in the range 
of movement functional outcome is good in most of the patients. 
2.4 Deterioration of consciousness 
A common cause of a decline in consciousness in bacterial meningitis is clinical evidence of 
cerebral edema. The release of proinflammatory mediators in the subarachnoid space leads 
to an inflammatory response in the central nervous system that contributes to an increased 
permeability of the blood–brain barrier, cerebral edema and increased intracranial pressure. 
Several supportive therapies have been described, although no therapy has been proved to 
have clinical efficacy. Nevertheless, in patients with impending cerebral herniation, 
monitoring of intracranial pressure may be considered, but the outcome is expected to be 
poor. The use of osmotic diuretics to control intracranial pressure may be an option, 
although there are no definitive data on the efficacy of this approach. (Figure 1) 
Seizures are other frequent cause of deteriorating consciousness with a higher mortality 
rate. They occur in about 20% of patients, that are older and more likely to have focal 
abnormalities on brain CT. S pneumoniae is the most usual causative micro organism. 
Patients with seizures or a clinical suspicion of prior seizure should receive anticonvulsant 
therapy, but the low incidence of this complication does not justify prophylaxis. A rare 
cause of the deterioration of consciousness in meningitis is nonconvulsive status epilepticus.  
Acute hydrocephalus can also complicate meningitis, because the purulent exudate 
interferes with CSF absorption by the arachnoid villi, resulting in communicating 
hydrocephalus. When the inflammatory exudate involves the basal cisterns and surrounds 
the cranial nerves at the base of the brain (basilar meningitis), it may block CSF flow at the 
foramina of Luschka and Magendie, resulting in obstructive hydrocephalus. 
Repeated lumbar puncture or the placement of a temporary lumbar drain may effectively 
reduce intracranial pressure. In patients with mild enlargement of the ventricular system 
with no clinical deterioration, a spontaneous resolution may occur, and invasive procedures 
are therefore withheld.  
Cerebral infarction due to arterial occlusion complicates bacterial meningitis in 10–15% of 
patients. Venous infarction due to septic venous thrombosis occurs in 3–5%. Cerebral 
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infarcts may involve large vascular territories and may cause brain swelling and a mass 
effect, which may result in a decline in consciousness Arteritis of small and medium-sized 
arteries and inflammatory involvement of veins is probably caused by tissue destructive 
agents, such as oxidants and proteolytic enzymes, released by activated leukocytes. 
Treatment is mainly supportive and these patients have a poor outcome. 
 
 
 
Fig. 1. Major Intracranial Complications in Bacterial Meningitis in Adults.  
2.5 Focal neurological complications 
In patients who develop focal neurological signs (hemiparesis, monoparesis, aphasia) some 
entities must be excluded: cerebral infarction (due to inflammatory occlusion of cerebral 
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arteries, septic venous thrombosis), seizures, subdural empyema or a combination of these 
causes. A brain CT scan is needed to rule out many of these causes. 
The possibility of septic intracranial venous thrombosis should be considered in patients 
with an impaired level of consciousness, seizures, fluctuating focal signs and stroke in non-
arterial distributions. MRI with venous-phase studies confirms the diagnosis. Treatment of 
cerebral thrombophlebitis in bacterial meningitis is directed toward the infection. 
Subdural empyema should be suspected in patients who have concomitant sinusitis or 
mastoiditis or who have recently undergone surgery for either of these disorders. In most 
cases contrast-enhanced brain CT will reveal the hypodense subdural collections (Figure 2). 
Brain MRI is more sensitive than CT in detecting subdural empyema along the convexity, 
and especially for infratentorial subdural empyema. Currently, MRI with diffusion-
weighted images (DWI) and apparent diffusion coefficient mapping (ADC) remains the 
preferred imaging modality for detecting subdural empyema. Subdural empyema should be 
surgically drained by craniotomy but the outcome is poor if the patient is unconscious. 
Abnormalities of the cranial nerves are caused by the meningeal inflammatory process or by 
an increase in cerebrospinal fluid pressure. The most frequent cranial-nerve abnormality is the 
involvement of the eighth cranial nerve, which is reflected in a hearing loss in 14 percent of 
patients. A cochlear implant may eventually be needed by some severely affected patients. 
 
 
Fig. 2. Frontal sinusitis, empyema, and abscess formation in a patient with bacterial 
meningitis. This contrast-enhanced, axial T1-weighted magnetic resonance image shows a 
right frontal parenchymal low intensity (edema), leptomeningitis (arrowheads), and a 
lentiform-shaped subdural empyema (arrows). 
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3. Aseptic meningitis 
Enteroviruses are the most common etiologic pathogens in persons with aseptic meningitis 
and do not require specific antimicrobial therapy. They can be diagnosed by CSF 
polymerase chain reaction testing (Kupila et al., 2006), which is not always needed, but a 
positive test may be useful in discontinuing antimicrobials initiated presumptively for 
bacterial meningitis.  
Herpes Simplex Virus (HSV) aseptic meningitis is usually a self-limited infection that must 
be distinguished from HSV encephalitis based on clinical and radiographic features. 
Therapy with acyclovir can be lifesaving in patients with HSV encephalitis. (Bamberg, 2010) 
In contrast with HSV encephalitis, most patients with HSV aseptic meningitis have normal 
mental status and neurologic function and do not have the temporal lobe enhancement 
observed on magnetic resonance imaging. Both forms of HSV central nervous system 
disease are diagnosed by CSF HSV polymerase chain reaction testing. Infection with HSV 
may cause recurrent disease (e.g., Mollaret meningitis). 
Varicella zoster virus infection may cause aseptic meningitis in the absence of cutaneous 
manifestations. Although it has not been studied in clinical trials, therapy with acyclovir at 
10 mg per kg every eight hours is suggested, based on expert opinion.  
Lyme disease, a systemic disease with dermatological, rheumatological, neurological, and 
cardiac manifestations, is caused by Borrelia burgdorferi and transmitted by the hard-shelled 
deer ticks: Ixodes dammini in the eastern United States, Ixodes pacificus in the western United 
States, and Ixodes ricinus in Europe. The existence of both early and late neurological 
manifestations, diagnostic uncertainty, and potential for relapse despite therapy have fueled 
continuing debate over the spectrum of Lyme-related neurological disease. Best agreement 
exists for the early neurological syndromes, which include lymphocytic meningitis, cranial 
neuropathy (commonly unilateral or bilateral Bell's palsy), and painful radiculoneuritis, 
which can occur alone or in combination. Optic neuritis, mononeuritis multiplex, and 
Guillain-Barré syndrome are other infrequent manifestations of early neurological 
involvement. Neurological complications of more advanced Lyme disease include 
encephalomyelitis, with predominant white matter involvement and peripheral neuropathy. 
Lymphocytic meningitis is usually acute, but may cause chronic or relapsing meningitis and 
communicating hydrocephalus. Radiculoneuritis, beginning as a painful limb disorder, may 
continue with exacerbations and remissions for up to 6 months. Encephalopathy with 
memory or cognitive abnormalities, confusional states, accelerated dementia, and normal 
CSF study results may occur. Other psychiatric or fatigue syndromes appear less likely to be 
causally related to Lyme disease. 
Borreliosis is treated with parenteral antibiotics if there is evidence that infection has crossed 
the blood-brain barrier. Ceftriaxone (2 g once daily intravenously) or penicillin (3 to 4 
million units intravenously every 3 to 4 hours) for 2 to 4 weeks are first-line drugs. 
Tetracycline and chloramphenicol are alternatives in penicillin- or cephalosporin-allergic 
patients. Routine use of corticosteroids is not indicated. Recommendations for the use of 
corticosteroids in neuroborreliosis generally have been limited to patients treated 
aggressively with intravenous antibiotics with evidence of severe inflammation that fails to 
improve. CSF examination should be performed toward the end of the 2- to 4-week 
treatment course to assess the need for continuing treatment and again 6 months after the 
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conclusion of therapy. Intrathecal antibody production may persist for years following 
successful treatment and in isolation does not indicate active disease. Patients in whom 
CSF pleocytosis fails to resolve within 6 months, should be retreated. Peripheral or cranial 
nerve involvement without CSF abnormalities may be treated with oral agents, either 
doxycycline, 100 mg twice daily for 14 to 21 days, or amoxicillin, 500 mg every 8 hours for 
10 to 21 days. 
Up to one third of untreated patients with syphilis develop late syphilis (tertiary syphilis), 
a slowly progressive inflammatory disease that includes gummatous (granulomatous), 
cardiovascular, and neurological forms. Early neurological manifestations of tertiary 
neurosyphilis include pure meningeal or meningovascular disease, with a 3- to 10-year 
latency period from primary infection, and parenchymal forms, which occur 10 to 30 
years after initial infection. General paresis refers to parenchymal cerebral involvement 
and tabes dorsalis to syphilitic myeloneuropathy. Syphilitic gummas, granulomas that 
present as space-occupying lesions in brain or cord, may occur at any stage of 
disseminated disease. 
Neurosyphilis spans all stages of disseminated disease. Meningeal, meningovascular, and 
parenchymal syndromes are perhaps best viewed as a continuum of disease, rather than as 
discrete disorders. Syphilitic meningitis, meningovascular syphilis, general paresis, and 
tabes are different clinical expressions of the same fundamental pathological events, 
specifically meningeal invasion, obliterative endarteritis, and parenchymal invasion. 
Especially in the antibiotic era, symptomatic neurosyphilis may present, not as one classic 
syndrome, but as mixed, subtle, or incomplete disease. All of the neurological complications 
of syphilis have been reported in HIV disease, which may accelerate the onset and 
progression of neurosyphilis. 
Syphilitic meningitis typically occurs earlier than other forms of neurosyphilis and is often 
asymptomatic. Rare complications of acute syphilitic meningitis include cranial neuropathy, 
hydrocephalus, myelitis, or lumbosacral radiculitis. Meningovascular syphilis usually 
occurs 4 to 7 years after primary infection (range, 6 months to 12 years). In addition to 
stroke, involvement of large and small cerebral vessels also causes headache, vertigo, 
insomnia, and psychiatric or personality disorders. 
Adequate treatment of neurosyphilis is based largely on achieving treponemicidal levels of 
penicillin in the CSF. Treponema pallidum is highly susceptible to penicillin, which is the drug 
of choice for all stages of syphilis. Serum levels of penicillin should be maintained for many 
days because treponemes divide slowly in early syphilis (30-33 per hour in experimental 
settings) and penicillin acts only on dividing cells. 
Therapy that is considered standard for non immunocompromised individuals with syphilis 
meningitis should remain the standard for immunocompromised individuals even with 
asymptomatic neurosyphilis. Either of the following is acceptable treatment: 
a. Aqueous (crystalline) penicillin-G at 2-4 million U intravenously every 4 hours; 
alternatively, continuously for 10-14 days, or 
b. Procaine penicillin-G at 2.4 million U/d intramuscularly plus probenecid at 500 mg 
orally 4 times per day for 10-14 days (probenecid increases brain concentrations of 
penicillin less than it increases CSF concentrations, but avoid using it if the patient has a 
history of serious allergy to sulfonamides)  
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Contraindications include documented hypersensitivity, use of penicillin in pregnant 
patients (usually safe but benefits must outweigh the risks), and impaired renal function 
(use caution).  
Other antibiotics, as alternative regimens, have not been studied sufficiently, and their 
routine use is not recommended. If patients are allergic to penicillin, either tetracycline or 
doxycycline probably is effective. Pregnant women should not receive doxycycline. 
Typically, tetracycline hydrochloride at 500 mg orally 4 times per day or doxycycline at 100 
mg orally twice daily for 4 weeks is prescribed. Defining the efficacy of azithromycin for 
early syphilis may simplify therapy. Incidentally, the emergence of azithromycin-resistant T 
pallidum has been reported. 
4. Tuberculous and cryptococcal meningitis 
A high index of suspicion is needed to diagnose tuberculous meningitis because culture 
results are often delayed and stains are often negative. Empiric therapy may be lifesaving. 
Polymerase chain reaction testing may be useful. Death may occur as a result of missed 
diagnoses and delayed treatment.  
Most of the guidelines follow the model of short-course chemotherapy of pulmonary 
tuberculosis: an "intensive phase" of treatment with four drugs, followed by treatment with 
two drugs during a prolonged "continuation phase". Initial treatment is a combination of 
isoniazid (5 mg per kg per day); rifampin (10 mg per kg per day, up to 600 mg); 
pyrazinamide (15 to 30 mg per kg per day, up to 2 g); and ethambutol (15 to 25 mg per kg 
per day). Streptomycin (20 to 40 mg per kg per day, up to 1 g) should be used instead of 
ethambutol in young children.  
Evidence concerning the duration of treatment is conflicting. The duration of conventional 
therapy is 6-9 months, although some investigators still recommend as many as 24 months 
of therapy. No guidelines exist as to the components and duration of treatment in the case of 
multidrug-resistant TBM.  
The use of corticosteroids in adults is controversial; they may be indicated in the presence of 
increased intracranial pressure, altered consciousness, focal neurological findings, spinal 
block, and tuberculous encephalopathy. Adding dexamethasone to the treatment regimen 
seems to improve mortality rate in patients older than 14 years with tuberculous meningitis. 
Cochrane systematic review concluded that overall adjunctive therapy with corticosteroids 
reduces the risk of death (relative risk (RR), 0.78). 
The potential complications include associated elevated intracranial pressure, 
hydrocephalus, vasculitis, acute seizures, and hyponatremia. Aggressive and appropriate 
treatment of these complications can minimize the secondary brain injury and improve the 
chance of a good outcome. Disturbances of sodium, intravascular volume and water are 
common in tuberculous meningitis. Hyponatremia occurs in 35% to 65% of patients. Acute 
seizures occur in about 50% of children and in 5% of adults. 
In these patients, associated space-occupying tuberculoma(s) may be the substrate for 
increased intracranial pressure (Figure 3). Growing evidence suggests that most 
tuberculomas resolve with antituberculous treatment. However, surgical excision is 
indicated in: tuberculoma causing obstructive hydrocephalus and significant increased 
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intracranial pressure; tuberculoma causing obstructive hydrocephalus and not resolving on 
medical treatment; large space-occupying tuberculomas with increased intracranial 
pressure; and tuberculomas with associated compartmental shifts and not resolving with 
medical treatment. (Marais, 2010; Murthy, 2010) 
 
 
Fig. 3. MRI with contrast showing classical ring enhancing lesions of tuberculomas 
Cryptococcal meningitis is the most common fungal meningitis, and usually occurs in 
patients with altered cellular immunity. It is estimated that the global burden of HIV-
associated cryptococcosis approximates 1 million cases annually worldwide. It is relevant 
that, despite access to advanced medical care and the availability of highly active 
antiretroviral therapy, the 3-month mortality rate during management of acute cryptococcal 
meningoencephalitis approximates 20%. Furthermore, without specific antifungal treatment 
for cryptococcal meningoencephalitis in certain HIV-infected populations, mortality rates of 
100% have been reported within 2 weeks after clinical presentation to health care facilities. 
(Perfect et al., 2010; Saag et al., 2000) 
Usually presents with headache, fever, stiff neck and photophobia. However, meningeal 
symptoms and signs may be minimal or absent in over one half of the cases, and the rather 
broad clinical spectrum includes personality change, cognitive impairment, cranial 
neuropathy, altered consciousness and coma.  
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The CSF profile ranges from striking protein elevation, mononuclear pleocytosis, and 
hypoglycorrhachia to minimal abnormalities that overlap with those attributable to HIV 
infection alone. Fungal CSF culture is the gold standard, but the time wasted before a 
positive result is obtained, limits its clinical utility. India ink smear is helpful when positive, 
but is too insensitive to exclude the diagnosis if negative. Fortunately, CSF cryptococcal 
antigen (CrAg) testing is a rapid, specific test with a sensitivity exceeding 90%. The diverse 
clinical presentations of cryptococcal meningitis enforce CrAg to be performed routinely in 
CSF of patients with AIDS. 
It is apparent that insightful management of cryptococcal disease is critical to a successful 
outcome. We should divide the treatment in three situations, as follows: 
a. In HIV infected individuals, the initial treatment (induction regiment) includes 
amphotericin B (0.7 to 1.0 mg/kg per day IV) with or without flucytosine (25 mg/kg 
every six hours orally) for 2 to 3 weeks. Renal insufficiency, hypokalemia, and 
hypomagnesemia may complicate amphotericin B therapy, and the hematological 
toxicity of flucytosine sometimes precludes its use in patients with AIDS, in whom 
pancytopenia is common. Patients who are doing well can be switched to fluconazole, 
200 mg twice a day for 8 to 10 weeks (maintenance therapy), and then placed on 
prophylactic therapy of 200 mg daily to prevent relapse. Alternatively Itraconazole can 
be used (200 mg twice per day orally; drug-level monitoring strongly advised). Active 
antiretroviral therapy should be initiated 2–10 weeks after the beginning of initial 
antifungal treatment. Consider discontinuing suppressive therapy during active 
antiretroviral therapy in patients with a CD4 cell count >100 cells/mL and an 
undetectable or very low HIV RNA level sustained for >3 months (minimum of 12 
months of antifungal therapy); but consider reinstitution of maintenance therapy if the 
CD4 cell count decreases to <100 cells/mL (B-III). 
b. In organ transplant recipients, the treatment includes liposomal amphotericin B (3–4 
mg/kg per day IV) or amphotericin B lipid complex (5 mg/kg per day IV) plus 
flucytosine (100 mg/kg per day in 4 divided doses) for at least 2 weeks for the 
induction regimen, followed by fluconazole (400–800 mg [6–12 mg/kg] per day orally) 
for 8 weeks initially, and (200–400 mg per day orally) for 6–12 months afterwards.  
c. Non-HIV Infected, Non transplant Hosts, the treatment includes amphotericin B (0.7–
1.0 mg/kg per day IV) plus flucytosine (100 mg/kg per day orally in 4 divided doses) 
for at least 4 weeks for induction therapy. The 4-week induction therapy is reserved for 
persons with meningoencephalitis without neurological complications and negative 
cerebrospinal fluid (CSF) yeast culture results after 2 weeks of treatment. For 
amphotericin B toxicity issues, lipid formulations of amphotericin B may be substituted 
in the second 2 weeks. In patients with neurological complications, consider extending 
induction therapy for a total of 6 weeks, and lipid formulations of amphotericin for the 
last 4 weeks of the prolonged induction period. Then, start consolidation with 
fluconazole (400 mg per day) for 8 weeks.  
Regarding neurological complications, some of them had already been described in 
complications of bacterial meningitis, as cerebral edema, increased intracranial pressure, 
acute hydrocephalus and abnormalities of the cranial nerves. Their management was 
described above. Poor prognostic features at presentation include impaired level of 
consciousness, CSF cell count less than 20 cells/μL, and CSF CrAg greater than 1:1024.  
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Another possible complication is the presence of cerebral cryptococcomas. The treatment 
consists of induction with amphotericin B (0.7–1 mg/kg per day IV), liposomal 
amphotericin B (3–4 mg/kg per day IV), or amphotericin B lipid complex (5 mg/kg per day 
IV) plus flucytosine (100 mg/kg per day orally in 4 divided doses) for at least 6 weeks. Then 
consolidation and maintenance therapy with fluconazole (400–800 mg per day orally) for 6–
18 months. Adjunctive therapies include corticosteroids for mass effect and surrounding 
edema and/or surgery for large masses (>3 cm lesion).  
5. Conclusions 
The management approach to patients with suspected or proven bacterial meningitis 
includes emergent CSF analysis, and initiation of appropriate antimicrobial and adjunctive 
therapies. The choice of empirical antimicrobial therapy is based on the patient’s age and 
underlying disease status; once the infecting pathogen is isolated, antimicrobial therapy can 
be modified for optimal treatment. 
The most important priority to reduce the burden of bacterial meningitis throughout the 
world must include the introduction and availability of effective vaccines against the 
common meningeal pathogens. 
Finally a higher index of suspicion is needed to diagnose tuberculous meningitis because 
culture results are often delayed, stains are often negative and empiric therapy may be 
lifesaving. A prompt diagnosis of meningitis is specially important in immunosuppressive 
patients, with high rates of mortality. 
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